Delayed versus immediate treatment for patients with acute hepatitis C: A randomised controlled non-inferiority trial

The Lancet Infectious Diseases

Volumn 13, Issue 6, 2013, Pages 497-506

  Deterding, Katja ^a,b   Grüner, Norbert ^a,c   Buggisch, Peter ^a,e   Wiegand, Johannes ^a,d   Galle, Peter R ^a,f   Spengler, Ulrich ^a,g   Hinrichsen, Holger ^a,h   Berg, Thomas ^a,d,i   Potthoff, Andrej ^a,b   Malek, Nisar ^a,j   Großhennig, Anika ^b   Koch, Armin ^b   Diepolder, Helmut ^a,c   Lüth, Stefan ^a,e   Feyerabend, Sandra ^a   Jung, Maria Christina ^a,c   Rogalska Taranta, Magdalena ^a,b   Schlaphoff, Verena ^a,b   Cornberg, Markus ^a,b   Manns, Michael P ^a,b   Wedemeyer, Heiner ^a,b   more..

^a Hep Net: German Network of Competence on Viral Hepatitis   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^g UNIVERSITY OF BONN   (Germany)

^h UNIVERSITY OF KIEL   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN;

ADULT; ARTICLE; ATTRIBUTABLE RISK; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERAPY DELAY; TREATMENT PLANNING; VIRAL CLEARANCE;

ACUTE DISEASE; ADULT; AGED; ANTIVIRAL AGENTS; COINFECTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; YOUNG ADULT;

EID: 84878454911     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70059-8     Document Type: Article

References (30)

1. Lavanchy D The global burden of hepatitis C. Liver Int 2009, 29(suppl 1):74-81.
2. Shepard CW, Finelli L, Alter MJ Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5:558-567.
3. Grebely J, Prins M, Hellard M, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 2012, 12:408-414. the International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3).
4. Martínez-Bauer E, Forns X, Armelles M, et al. Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J Hepatol 2008, 48:20-27. the Spanish Acute HCV Study Group.
5. Deterding K, Wiegand J, Grüner N, Wedemeyer H Medical procedures as a risk factor for HCV infection in developed countries: do we neglect a significant problem in medical care?. J Hepatol 2008, 48:1019-1020.
6. Deterding K, Wiegand J, Grüner N, et al. The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. Z Gastroenterol 2009, 47:531-540.
7. Terrault NA, Dodge JL, Murphy EL, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology 2012, published online Nov 23. 10.1002/hep.26164.
8. Wiegand J, Deterding K, Cornberg M, Wedemeyer H Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha. J Antimicrob Chemother 2008, 62:860-865.
9. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003, 125:80-88.
10. Mosley JW, Operskalski EA, Tobler LH, et al. Viral and host factors in early hepatitis C virus infection. Hepatology 2005, 42:86-92.
11. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138:1338-1345.
12. Tillmann HL, Thompson AJ, Patel K, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010, 139:1586-1592.
13. Beinhardt S, Aberle JH, Strasser M, et al. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology 2012, 142:78-85.
14. Grebely J, Petoumenos K, Hellard M, et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010, 52:1216-1224. the ATAHC Study Group.
15. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
16. Santantonio T, Wiegand J, Gerlach JT Acute hepatitis C: current status and remaining challenges. J Hepatol 2008, 49:625-633.
17. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55:245-264. European Association for the Study of the Liver.
18. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:1433-1444. the American Association for Study of Liver Diseases.
19. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001, 345:1452-1457. the German Acute Hepatitis C Therapy Group.
20. Wiegand J, Buggisch P, Boecher W, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006, 43:250-256. the German HEP-NET Acute HCV Study Group.
21. De Rosa FG, Bargiacchi O, Audagnotto S, et al. Twelve-week treatment of acute hepatitis C virus with pegylated interferon-alpha-2b in injection drug users. Clin Infect Dis 2007, 45:583-588.
22. Delwaide J, Bourgeois N, Gérard C, et al. Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment is the most effective predictive factor of sustained viral response. Aliment Pharmacol Ther 2004, 20:15-22. the Belgian Association for the Study of the Liver (BASL).
23. Dintsios CM, Haverkamp A, Wiegand J, et al. Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany. Eur J Gastroenterol Hepatol 2010, 22:278-288.
24. Manns MP, Meyer S, Wedemeyer H The German network of excellence for viral hepatitis (Hep-Net). Hepatology 2003, 38:543-544.
25. Broers B, Helbling B, François A, et al. Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 2005, 42:323-328. the Swiss Association for the Study of the Liver (SASL 18).
26. Grebely J, Matthews GV, Hellard M, et al. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol 2011, 55:76-85. the ATAHC Study Group.
27. Grebely J, Petoumenos K, Matthews GV, et al. Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study. Drug Alcohol Depend 2010, 107:244-249. the ATAHC Study Group.
28. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000, 343:1666-1672.
29. Manns MP, Wedemeyer H, Cornberg M Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006, 55:1350-1359.
30. Dusheiko G, Wedemeyer H New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye. Gut 2012, 61:1647-1652.